Effect of anti-IL17 and/or Rho-kinase inhibitor treatments on vascular remodeling induced by chronic allergic pulmonary inflammation

Autor(es):Mostrar menos -

dos Santos, Tabata M. ^{[1, 2]} ; Righetti, Renato F. ^{[1, 2]} ; Rezende, Bianca G. ^[2] ; Campos, Elaine C. ^{[1, 2]} ; Camargo, Leandro do N. ^{[1, 2]} ; Saraiva-Romanholo, Beatriz M. ^{[3, 2]} ; Fukuzaki, Silvia ^[2] ; Prado, Carla M. ^[4] ; Leick, Edna A. ^[2] ; Martins, Milton A. ^[2] ; Tiberio, Iolanda F. L. C. ^[5]

Afiliação do(s) autor(es)

^[1] Hosp Sirio Libanes, Sao Paulo - Brazil

^[2] Univ Sao Paulo, Fac Med, FMUSP, Sao Paulo, SP - Brazil

^[3] Univ City Sao Paulo UNICID, Dept Med, Sao Paulo - Brazil

^[4] Univ Fed Sao Paulo, Dept Biosci, Santos, SP - Brazil

^[5] Univ Sao Paulo, Dept Clin Med, Fac Med, Av Dr Arnaldo 455, Sala 1210, BR-01246903 Sao Paulo, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE; v. 14, DEC 2020.
• Citações Web of Science: 0

Resumo

Background and aims: Expansion and morphological dysregulation of the bronchial vascular network occurs in asthmatic airways. Interleukin (IL) -17 and Rho-kinase (ROCK) are known to act in inflammation control and remodeling. Modulation of Rho-kinase proteins and IL-17 may be a promising approach for the treatment of asthma through the control of angiogenesis. Our objective was to analyze the effects of treatment with anti-IL17 and/or Rho-kinase inhibitor on vascular changes in mice with chronic allergic pulmonary inflammation. Methods: Sixty-four BALB/c mice, with pulmonary inflammation induced by ovalbumin were treated with anti-IL17A (7.5/mu g per dose, intraperitoneal) and/or Rho-kinase inhibitor (Y-27632-10 mg/kg, intranasal), 1 h before each ovalbumin challenge (22, 24, 26, and 28/days). Control animals were made to inhale saline. At the end of the protocol, lungs were removed, and morphometric analysis was performed to quantify vascular inflammatory, remodeling, and oxidative stress responses. Results: Anti-IL17 or Rho-kinase inhibitor reduced the number of CD4(+), CD8(+), dendritic cells, IL-4, IL-5, IL-6, IL-10, IL-13, IL-17, Rho-kinase 1 and 2, transforming growth factor (TGF-beta), vascular endothelial growth factor (VEGF), nuclear factor (NF)-KappaB, iNOS, metalloproteinase (MMP)-9, MMP-12, metalloproteinase inhibitor-1 (TIMP-1), FOXP-3, signal transducer and activator of transcription 1 (STAT1) and phospho-STAT1-positive cells, and actin, endothelin-1, isoprostane, biglycan, decorin, fibronectin and the collagen fibers volume fraction compared with the ovalbumin group (p < 0.05). The combination treatment, when compared with anti-IL17, resulted in potentiation of decrease in the number of IL1 beta- and dendritic cells-positive cells. When we compared the OVA-RHO inhibitor-anti-IL17 with OVA-RHO inhibitor we found a reduction in the number of CD8(+) and IL-17, TGF-beta, and phospho-STAT1-positive cells and endothelin-1 in the vessels (p < 0.05). There was an attenuation in the number of ROCK 2-positive cells in the group with the combined treatment when compared with anti-IL17 or Rho-kinase inhibitor-treated groups (p < 0.05). Conclusion: We observed no difference in angiogenesis after treatment with Rho-kinase inhibitor and anti-IL17. Although the treatments did not show differences in angiogenesis, they showed differences in the markers involved in the angiogenesis process contributing to inflammation control and vascular remodeling. The reviews of this paper are available via the supplemental material section. (AU)

• Processo FAPESP: 18/02537-5 - Caracterização da síndrome de sobreposição asma-DPOC (ACOS): estudos experimentais e clínicos
• Beneficiário: Iolanda de Fátima Lopes Calvo Tibério
• Modalidade de apoio: Auxílio à Pesquisa - Temático